Roy Buchanan
Stock Analyst at JMP Securities
(5.00)
# 14
Out of 5,117 analysts
71
Total ratings
55.07%
Success rate
109.69%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $153 → $173 | $221.32 | -21.83% | 8 | Oct 3, 2025 | |
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $32.31 | +17.61% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $15.41 | +107.66% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $13.91 | +79.73% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $4.50 | +211.46% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $4.66 | +114.59% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.07 | +86.92% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.59 | +1,032.08% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $67.65 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $3.81 | +4.99% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $14 | $4.59 | +205.01% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $123.23 | -73.22% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.71 | +6.16% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $800.88 | -44.06% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $12.19 | +31.26% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.88 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Oct 3, 2025
Maintains: Market Outperform
Price Target: $153 → $173
Current: $221.32
Upside: -21.83%
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $32.31
Upside: +17.61%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $15.41
Upside: +107.66%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $13.91
Upside: +79.73%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $4.50
Upside: +211.46%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $4.66
Upside: +114.59%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.07
Upside: +86.92%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.59
Upside: +1,032.08%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $67.65
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $3.81
Upside: +4.99%
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $4.59
Upside: +205.01%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $123.23
Upside: -73.22%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.71
Upside: +6.16%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $800.88
Upside: -44.06%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $12.19
Upside: +31.26%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.88
Upside: -